​

Genprex Stock (NASDAQ:GNPX)

OwnershipFinancialsChart
Genprex by TradingView

Previous Close

$0.27

52W Range

$0.22 - $4.09

50D Avg

$0.37

200D Avg

$0.93

Market Cap

$6.39M

Avg Vol (3M)

$4.06M

Beta

-0.39

Div Yield

-

GNPX Company Profile

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

15

IPO Date

Mar 29, 2018

Website

GNPX Performance

GNPX Financial Summary

Dec 24Dec 23Dec 22
Revenue---
Operating Income-$-31.08M$-23.83M
Net Income$-21.39B$-30.86M$-29.46M
EBITDA-$-31.06M$-23.81M
Basic EPS$-5.34K$-22.58$-24.59
Diluted EPS$-5.34K$-22.56$-24.58

Fiscal year ends in Dec 24 | Currency in USD

Peer Comparison

TickerCompany
HEPAHepion Pharmaceuticals, Inc.
RNAZTransCode Therapeutics, Inc.
MREOMereo BioPharma Group plc
GLSIGreenwich LifeSciences, Inc.
EYENEyenovia, Inc.
CGTXCognition Therapeutics, Inc.
KODKodiak Sciences Inc.
XFORX4 Pharmaceuticals, Inc.
RVPHReviva Pharmaceuticals Holdings, Inc.
ELEVElevation Oncology, Inc.